FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker(Erasmus University Rotterdam), Bas Groot Koerkamp, Andrea Wang‐Gillam(Washington University in St. Louis), Jason E. Faris(Royal Marsden NHS Foundation Trust), Thierry Conroy(Inserm), Julien Taı̈eb(Paris Cardiovascular Research Center), Ian Chau(Universitat Autònoma de Barcelona), Florian Hohla(University of Salzburg), Ravi Shridhar(Florida Hospital Cancer Institute), Eran Sadot(Memorial Sloan Kettering Cancer Center), Sing Yu Moorcraft(National Health Service), Theodore S. Hong(University of Massachusetts Chan Medical School), Lysiane Marthey(Hôpital Antoine-Béclère), Jill Lacy(Smilow Cancer Hospital), Bassel F. El‐Rayes(Emory University), Peter J. Hosein(Markey Cancer Center), Berend R. Beumer(Erasmus University Rotterdam), Eric A. Mellon(Moffitt Cancer Center), Peter J. Allen(Memorial Sloan Kettering Cancer Center), Casper H.J. van Eijck(Erasmus MC)
Cited by 914
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k